OAS1: Key Regulator of T-Cell Receptor and Cancer (G4938)

Target Name: OAS1

NCBI ID: G4938

OAS1

OAS1: Key Regulator of T-Cell Receptor and Cancer

OAS1 (OAs1), also known as E18 or E16, is a protein that is expressed in various tissues throughout the body, including the brain, heart, and lungs. It is a key regulator of cell signaling pathways and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key functions of OAS1 is its role in the regulation of the T-cell receptor (TCR), a critical signaling pathway that helps coordinate the immune response. TCR is a transmembrane protein that is expressed in the T-cells and plays a crucial role in their development, activation, and function. OAS1 has been shown to regulate TCR signaling by interacting with its extracellular domain, which contains a number of critical protein-protein interactions that are critical for TCR function.

In addition to its role in TCR signaling, OAS1 is also involved in the regulation of several other signaling pathways, including the production of reactive oxygen species (ROS), which can damage cellular components and contribute to a number of diseases, including cancer. OAS1 has been shown to regulate the production of ROS by interacting with a variety of protein targets, including NAD+-dependent enzymes that are involved in the production of ROS.

The role of OAS1 in cancer is particularly concerning, as high levels of OAS1 have been observed in a number of cancer types. For example, OAS1 has been shown to be overexpressed in a variety of cancer tissues, and studies have suggested that inhibiting OAS1 activity may be a promising therapeutic approach for cancer treatment. In addition to its potential as a therapeutic target, OAS1 is also an attractive biomarker for cancer, as its expression levels can be easily measured and correlated with clinical outcomes.

OAS1 has also been implicated in a number of other diseases and disorders, including neurodegenerative diseases and autoimmune disorders. For example, OAS1 has been shown to be involved in the regulation of the production of neurotransmitters, such as dopamine and serotonin, which are critical for the functioning of the nervous system. In addition, OAS1 has been shown to play a role in the regulation of the immune response, as it has been implicated in the development of autoimmune disorders.

Despite the many promising studies on OAS1, much more research is needed to fully understand its role in these diseases and to develop effective therapies based on its properties. One approach that may be promising is the use of small molecules that can modulate OAS1 activity, such as inhibitors of OAS1-interacting proteins or modulators of OAS1-regulated signaling pathways. Additionally, efforts to understand the full complexity of OAS1 function will be necessary to fully appreciate its potential as a drug target and biomarker.

In conclusion, OAS1 is a protein that has important roles in several critical signaling pathways, including T-cell receptor signaling, ROS production, and cancer development. Its potential as a drug target and biomarker make it an important area of research for the development of new therapies for a variety of diseases. Further studies are needed to fully understand its role in these processes and to develop effective therapies based on its properties.

Protein Name: 2'-5'-oligoadenylate Synthetase 1

Functions: Interferon-induced, dsRNA-activated antiviral enzyme which plays a critical role in cellular innate antiviral response (PubMed:34581622). In addition, it may also play a role in other cellular processes such as apoptosis, cell growth, differentiation and gene regulation. Synthesizes higher oligomers of 2'-5'-oligoadenylates (2-5A) from ATP which then bind to the inactive monomeric form of ribonuclease L (RNase L) leading to its dimerization and subsequent activation. Activation of RNase L leads to degradation of cellular as well as viral RNA, resulting in the inhibition of protein synthesis, thus terminating viral replication (PubMed:34581622, PubMed:34145065). Can mediate the antiviral effect via the classical RNase L-dependent pathway or an alternative antiviral pathway independent of RNase L. The secreted form displays antiviral effect against vesicular stomatitis virus (VSV), herpes simplex virus type 2 (HSV-2), and encephalomyocarditis virus (EMCV) and stimulates the alternative antiviral pathway independent of RNase L

The "OAS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OAS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets